Kunio Yui

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4174061/publications.pdf

Version: 2024-02-01

430442 433756 46 980 18 31 h-index citations g-index papers 48 48 48 1340 docs citations citing authors all docs times ranked

#	Article	IF	CITATIONS
1	Potent serotonin (5-HT)2A receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome. Brain Research, 2001, 890, 23-31.	1.1	143
2	Effects of Large Doses of Arachidonic Acid Added to Docosahexaenoic Acid on Social Impairment in Individuals With Autism Spectrum Disorders. Journal of Clinical Psychopharmacology, 2012, 32, 200-206.	0.7	88
3	Studies of Amphetamine or Methamphetamine Psychosis in Japan: Relation of Methamphetamine Psychosis to Schizophrenia. Annals of the New York Academy of Sciences, 2000, 914, 1-12.	1.8	82
4	Eicosanoids Derived From Arachidonic Acid and Their Family Prostaglandins and Cyclooxygenase in Psychiatric Disorders. Current Neuropharmacology, 2015, 13, 776-785.	1.4	74
5	Oxidative Stress and Nitric Oxide in Autism Spectrum Disorder and Other Neuropsychiatric Disorders. CNS and Neurological Disorders - Drug Targets, 2016, 15, 587-596.	0.8	57
6	Tandospirone potentiates the fluoxetine-induced increases in extracellular dopamine via 5-HT1A receptors in the rat medial frontal cortex. Neurochemistry International, 2002, 40, 355-360.	1.9	51
7	Risperidone attenuates and reverses hyperthermia induced by 3,4-methylenedioxymethamphetamine (MDMA) in rats. NeuroToxicology, 2008, 29, 1030-1036.	1.4	49
8	Oseltamivir (Tamiflu $\hat{A}^{@}$) increases dopamine levels in the rat medial prefrontal cortex. Neuroscience Letters, 2008, 438, 67-69.	1.0	41
9	Mitochondrial Dysfunction and Its Relationship with mTOR Signaling and Oxidative Damage in Autism Spectrum Disorders. Mini-Reviews in Medicinal Chemistry, 2015, 15, 373-389.	1.1	32
10	Increased ω-3 polyunsaturated fatty acid/arachidonic acid ratios and upregulation of signaling mediator in individuals with autism spectrum disorders. Life Sciences, 2016, 145, 205-212.	2.0	29
11	Methamphetamine Psychosis. Journal of Clinical Psychopharmacology, 1997, 17, 34-43.	0.7	29
12	Perospirone, a novel atypical antipsychotic drug, potentiates fluoxetine-induced increases in dopamine levels via multireceptor actions in the rat medial prefrontal cortex. Neuroscience Letters, 2004, 364, 16-21.	1.0	28
13	Stress induced spontaneous recurrence of methamphetamine psychosis: the relation between stressful experiences and sensitivity to stress. Drug and Alcohol Dependence, 2000, 58, 67-75.	1.6	25
14	Susceptibility to subsequent episodes of spontaneous recurrence of methamphetamine psychosis Institute at which the work was carried out: Department of Legal Medicine and Human Genetics, Jichi Medical School, Minamikawachi, Tochigi 329-0498, Japan, and Medical Care Section, Tochigi Prison, 140, 140, 140, 140, 140, 140, 140, 140	1.6	25
15	2001, 64, 133-142. The Role of Noradrenergic and Dopaminergic Hyperactivity in the Development of Spontaneous Recurrence of Methamphetamine Psychosis and Susceptibility to Episode Recurrence. Annals of the New York Academy of Sciences, 2004, 1025, 296-306.	1.8	21
16	Factors for Susceptibility to Episode Recurrence in Spontaneous Recurrence of Methamphetamine Psychosis. Annals of the New York Academy of Sciences, 2002, 965, 292-304.	1.8	21
17	Increased Sensitivity to Stress in Spontaneous Recurrence of Methamphetamine Psychosis: Noradrenergic Hyperactivity With Contribution From Dopaminergic Hyperactivity. Journal of Clinical Psychopharmacology, 2000, 20, 165-174.	0.7	20
18	Susceptibility to Subsequent Episodes in Spontaneous Recurrence of Methamphetamine Psychosis. Annals of the New York Academy of Sciences, 2000, 914, 292-302.	1.8	19

#	Article	IF	Citations
19	Effects of constant daylight exposure during early development on marmoset psychosocial behavior. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 1493-1498.	2.5	17
20	Down-regulation of a signaling mediator in association with lowered plasma arachidonic acid levels in individuals with autism spectrum disorders. Neuroscience Letters, 2016, 610, 223-228.	1.0	17
21	Decreased total antioxidant capacity has a larger effect size than increased oxidant levels in urine in individuals with autism spectrum disorder. Environmental Science and Pollution Research, 2017, 24, 9635-9644.	2.7	17
22	Reduced endogenous urinary total antioxidant power and its relation of plasma antioxidant activity of superoxide dismutase in individuals with autism spectrum disorder. International Journal of Developmental Neuroscience, 2017, 60, 70-77.	0.7	12
23	A cross-species socio-emotional behaviour development revealed by a multivariate analysis. Scientific Reports, 2013, 3, 2630.	1.6	11
24	Plasma monoamine metabolites and spontaneous recurrence of methamphetamine-induced paranoid-hallucinatory psychosis: relation of noradrenergic activity to the occurrence of flashbacks. Psychiatry Research, 1996, 63, 93-107.	1.7	7
25	Improvement in Impaired Social Cognition but Not Seizures by Everolimus in a Child with Tuberous Sclerosis-Associated Autism through Increased Serum Antioxidant Proteins and Oxidant/Antioxidant Status. Case Reports in Pediatrics, 2019, 2019, 1-10.	0.2	7
26	The role of lipid peroxidation in individuals with autism spectrum disorders. Metabolic Brain Disease, 2020, 35, 1101-1108.	1.4	7
27	Methamphetamine plus scopolamine potentiates behavioral sensitization and conditioning. European Journal of Pharmacology, 1995, 279, 135-142.	1.7	6
28	Susceptibility to Episode Recurrence in Spontaneous Recurrence of Methamphetamine Psychosis. Journal of Clinical Psychopharmacology, 2003, 23, 525-528.	0.7	6
29	Psycho-Cognitive Intervention for ASD from Cross-Species Behavioral Analyses of Infants, Chicks and Common Marmosets. CNS and Neurological Disorders - Drug Targets, 2016, 15, 578-586.	0.8	6
30	Monoamine Neurotransmitter Function and Spontaneous Recurrence of Methamphetamine Psychosis. Annals of the New York Academy of Sciences, 1996, 801, 415-429.	1.8	5
31	Effects of repeated treatment with methamphetamine plus scopolamine and methamphetamine on behavioral sensitization and conditioning. Behavioural Brain Research, 1996, 80, 169-175.	1.2	5
32	Behavioral Responses Induced by Repeated Treatment with Methamphetamine Alone and in Combination with Scopolamine in Rats. Neuropsychobiology, 1996, 33, 21-27.	0.9	4
33	Monoamine Neurotransmitter Metabolites and Spontaneous Recurrence of Methamphetamine Psychosis. Brain Research Bulletin, 1997, 43, 25-33.	1.4	4
34	Urinary and Plasma Antioxidants in Behavioral Symptoms of Individuals With Autism Spectrum Disorder. Frontiers in Psychiatry, 2021, 12, 684445.	1.3	4
35	Competitive Interaction Between Plasma Omega-3 Fatty Acids and Arachidonic Acid is Related to Down-Regulation of A Signaling Mediator. Medicinal Chemistry, 2016, 12, 318-327.	0.7	3
36	Increased sensitivity to stress associated with noradrenergic hyperactivity, involving dopaminergic hyperactivity in spontaneous recurrences in methamphetamine psychosis. Addiction Biology, 2000, 5, 343-350.	1.4	2

#	Article	IF	CITATIONS
37	Editorial (Thematic Issue: New Therapeutic Targets for Autism Spectrum Disorders). CNS and Neurological Disorders - Drug Targets, 2016, 15, 529-532.	0.8	2
38	Contribution of Transferrin and Ceruloplasmin Neurotransmission and Oxidant/Antioxidant Status to the Effects of Everolimus: A Case Series. Cureus, 2020, 12, e6920.	0.2	2
39	Comparison of Behavioural Effects of Repeated Treatment with Methamphetamine plus Scopolamine and Methamphetamine Alone on Behavioural Sensitization and Conditioned Response. Journal of Pharmacy and Pharmacology, 2011, 47, 852-856.	1.2	1
40	Therapeutic Potential of Everolimus on Core Autism Symptoms and Increasing Serum Ceruloplasmin and Transferrin Levels in a Pubescent Boy with Tuberous Sclerosis. Neonatal and Pediatric Medicine, 2017, 03, .	0.1	1
41	Preface: Recent advances of neurobiological basis of stimulant-induced sensitization. Addiction Biology, 2000, 5, 321-324.	1.4	0
42	Neurobiological and Molecular Bases of Methamphetamine-Induced Behavioral Sensitization and Spontaneous Recurrence of Methamphetamine Psychosis, and its Implication in Schizophrenia. Current Psychiatry Reviews, 2006, 2, 381-393.	0.9	0
43	EDITORIAL (Thematic Issue: New Targets of Medical Treatment in Psychiatric Disorders). Current Neuropharmacology, 2015, 13, 736-738.	1.4	0
44	Editorial (Thematic Issue: Mitochondrial Dysfunction and Its Relation to Translocator Protein,) Tj ETQq0 0 0 rgBT	Overlock	10 Tf 50 467 0
	353-354.		
45	Monoamine Metabolites Analysis in Blood and the Relation to Flashback Occurrence in Methamphetamine Psychosis. Japanese Journal of Science and Technology for Identification, 1998, 3, 37-48.	0.2	O
46	Lipid Peroxidation With Implication of Organic Pollution in Autistic Behaviors. Cureus, 2021, 13, e14188.	0.2	0